G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 100.6 INR -2.89% Market Closed
Market Cap: ₹134.9B

Operating Margin

25%
Current
Declining
by 2.7%
vs 3-y average of 27.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
25%
=
Operating Income
₹5.5B
/
Revenue
₹22B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
25%
=
Operating Income
₹5.5B
/
Revenue
₹22B

Peer Comparison

Country Company Market Cap Operating
Margin
IN
Glenmark Life Sciences Ltd
NSE:GLS
134.9B INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Higher than 86% of companies in India
Percentile
86th
Based on 5 437 companies
86th percentile
25%
Low
-153 833.3% — 2.7%
Typical Range
2.7% — 13.2%
High
13.2% — 9 977%
Distribution Statistics
India
Min -153 833.3%
30th Percentile 2.7%
Median 7.3%
70th Percentile 13.2%
Max 9 977%

Glenmark Life Sciences Ltd
Glance View

Market Cap
134.9B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd., a spin-off from the parent company Glenmark Pharmaceuticals, has carved out its niche in the competitive world of active pharmaceutical ingredients (APIs). This Mumbai-based entity emerged as an independent public company, growing its presence in both the domestic and international markets. Glenmark Life Sciences strategically focuses on the manufacture and supply of high-quality APIs used across a diverse range of therapeutic areas including cardiovascular, central nervous system disorders, diabetes, pain management, and oncology. By maintaining a robust portfolio of over 120 APIs, the company ensures its penetration in the growing pharmaceutical sector, which increasingly demands reliable and efficient raw materials for drug production. Through its four state-of-the-art manufacturing facilities, Glenmark Life Sciences capitalizes on its well-established research and development capabilities to enhance its manufacturing processes and expand its product range. The company's business model is meticulously designed around long-term relationships with major pharmaceutical players, fostering partnerships that drive consistent revenue streams. By leveraging cost-effective manufacturing practices and an expansive distribution network across major pharmaceutical markets, Glenmark Life Sciences not only optimizes its production capabilities but also ensures timely delivery and high-quality standards. The company's success rests on its ability to balance operational efficiency with strategic expansion into high-growth markets, reinforcing its reputation as a reliable API supplier in the global pharmaceutical industry.

GLS Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
25%
=
Operating Income
₹5.5B
/
Revenue
₹22B
What is Glenmark Life Sciences Ltd's current Operating Margin?

The current Operating Margin for Glenmark Life Sciences Ltd is 25%, which is below its 3-year median of 27.6%.

How has Operating Margin changed over time?

Over the last 3 years, Glenmark Life Sciences Ltd’s Operating Margin has decreased from 29.4% to 25%. During this period, it reached a low of 25% on Sep 30, 2024 and a high of 29.7% on Dec 31, 2021.

Back to Top